Advertisement


Related Videos

David A. Hyman, MD, JD, on Inclusive Shared Savings

Opportunities to Optimize Cancer Policies Panel Discussion

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Varsha Gandhi, PhD, on Ibrutinib

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Advertisement

Advertisement




Advertisement